Lymphoma Treatment Market Size, Share & Trends Analysis Report By Type (Hodgkin Lymphoma, Non-Hodgkin Lymphoma), By Drugs (Adcetris, Rituxan, Imbruvica, Keytruda, Revlimid, Opdivo), By Region, And Segment Forecasts, 2019 - 2026

Published: Oct, 2019 | Pages: 185 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The global lymphoma treatment market size is expected to reach USD 26.4 billion by 2026, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 9.5%. Rising research activities for development of new treatments and increasing product line extension are likely to expedite growth. Increasing commercialization of novel drugs are further expected to drive the growth.

Availability of wide variety of products is further expected to aid growth. For instance, in January 2019, BeiGene received a breakthrough therapy designation by the U.S. FDA for its product Zanubrutinib for treating mantle cell lymphoma in adults. This drug is currently in late-stage clinical trial and is expected to be launched during the forecast period.

Growing awareness about early diagnosis of lymphoma among healthcare professionals & patients and rising government funding for R&D are some factors expected to propel market growth. For instance, institutes such as National Cancer Institute receives funding from the U.S. Congress to support cancer-related research and associated activities.

Further key findings from the report suggest:

• Non-Hodgkin lymphoma held the largest share in 2018 owing to prevalence of non-Hodgkin lymphoma and presence of blockbuster drugs.

• Hodgkin lymphoma is expected to be the fastest growing segment due to presence of strong product pipeline and increase in the number of label extension for existing drugs.

• Based on drug, Revlimid held the highest share in 2018 and is expected to grow at a significant rate during the forecast period. This can be attributed to growing use of this product in cancer treatment regimens.

• Rituxan/MabThera held the second largest share in 2018 owing to increasing use of this product in multiple indications and high prescription rate in major markets such as the U.S., Europe, and Japan.

• North America dominated in 2018, followed by Europe. This can be attributed to well-established healthcare infrastructure, high R&D expenditure, availability of novel drugs, and presence of key players.

• Asia Pacific is expected to be the fastest growing over the forecast period owing to increase in commercialization of products, rise in awareness about diseases and high unmet clinical needs.

• Some of the major players are Celgene Corporation; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd.; Seattle Genetics, Inc.; Merck & Co., Inc.; Johnson & Johnson; Takeda Pharmaceutical Company Ltd.; Abbott Laboratories; and Eli Lilly and Company.

• Key players for lymphoma treatment market are adopting strategies such as collaborations, mergers & acquisitions, product development, product line extension, and regional expansion to increase their share. For instance, Seattle Genetics collaborated with Takeda Pharmaceuticals for commercialization of Adcetris in different regions other than North America.

 Table of Contents

Chapter 1. Methodology and Scope
                    1.1.Market Segmentation & Scope
                    1.2. Market Definition
                    1.3. Information Procurement
                        1.3.1. Purchased database
                        1.3.2. GVR's internal database
                        1.3.3. Secondary sources & third party perspectives
                        1.3.4. Primary research
                    1.4. Information Analysis
                        1.4.1. Data analysis models
                    1.5. Market Formulation & Data Visualization
                    1.6. Data Validation & Publishing

Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Outlook
                    2.3. Competitive Insights

Chapter 3. Lymphoma Treatment Market Variables, Trends & Scope
                    3.1. Penetration & Growth Prospect Mapping
                    3.2. Regulatory Framework
                        3.2.1. Reimbursement framework
                    3.3. Market Dynamics
                        3.3.1. Market driver analysis
                            3.3.1.1. Growing incidence of lymphoma
                            3.3.1.2. Strong product pipeline
                            3.3.1.3. Rising label extension
                        3.3.2. Market restraint analysis
                            3.3.2.1. Patent expiry of blockbuster drugs
                    3.4. Lymphoma Treatment Market Analysis Tools
                        3.4.1. Industry analysis - Porter's
                            3.4.1.1. Supplier power (Moderate due to requirement of high-quality raw materials)
                            3.4.1.2. Buyer power (Moderate due to limited number of established providers)
                            3.4.1.3. Substitution threat (Moderate due to clinical development of new compounds)
                            3.4.1.4. New entrants' threat (Low due to huge capital investment)
                            3.4.1.5. Competitive rivalry (Moderate due to presence of few key players)
                        3.4.2. PESTEL analysis
                            3.4.2.1. Political landscape
                            3.4.2.2. Environmental landscape
                            3.4.2.3. Social landscape
                            3.4.2.4. Technology landscape
                            3.4.2.5. Legal landscape
                        3.4.3. Major deals & strategic alliances analysis
                            3.4.3.1. Joint ventures
                            3.4.3.2. Mergers & acquisitions

Chapter 4. Lymphoma Treatment Market - Competitive Analysis
                    4.1. Recent Developments & Impact Analysis, by Key Market Participants
                    4.2. Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
                    4.3. Public Companies
                        4.3.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
                        4.3.2. Company market share
                        4.3.3. Synergy analysis: Major deals & strategic alliances
                    4.4. Private Companies
                        4.4.1. List of key emerging companies
                        4.4.2. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience)

Chapter 5. Lymphoma Treatment Market: Type Estimates & Trend Analysis
                    5.1. Definitions & Scope
                    5.2. Type Market Share Analysis, 2018 & 2026
                    5.3. Lymphoma Treatment Market, by Type, 2015 to 2026
                    5.4. Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the following,
                        5.4.1. Hodgkin Lymphoma
                            5.4.1.1 Hodgkin lymphoma market, 2015 - 2026 (USD Million)
                        5.4.2. Non-Hodgkin Lymphoma
                            5.4.2.1 Non-Hodgkin lymphoma market, 2015 - 2026 (USD Million)

Chapter 6. Lymphoma Treatment Market: Drug Estimates & Trend Analysis
                    6.1. Definitions & Scope
                    6.2. Drug Market Share Analysis, 2018 & 2026
                    6.3. Lymphoma Treatment Market, by Drug, 2015 to 2026
                    6.4. Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the following,
                        6.4.1. Adcetris
                            6.4.1.1 Adcetris market, 2015 - 2026 (USD Million)
                        6.4.2. Opdivo
                            6.4.2.1 Opdivo market, 2015 - 2026 (USD Million)
                        6.4.3. Rituxan/MabThera
                            6.4.3.1 Rituxan/MabThera market, 2015 - 2026 (USD Million)
                        6.4.4. Imbruvica
                            6.4.4.1 Imbruvica market, 2015 - 2026 (USD Million)
                        6.4.5. Keytruda
                            6.4.5.1 Keytruda market, 2015 - 2026 (USD Million)
                        6.4.6. Revlimid
                            6.4.6.1 Revlimid market, 2015 - 2026 (USD Million)
                        6.4.7. Others
                            6.4.7.1 Others market, 2015 - 2026 (USD Million)

Chapter 7 Lymphoma Treatment Market: Regional Estimates & Trend Analysis, by Drug
                    7.1 Lymphoma Treatment Market: Regional Movement Analysis, 2018 & 2026
                    7.2 Lymphoma Treatment Market: Leading Players, 2018:
                        7.2.1. North America
                        7.2.2. Europe
                        7.2.3. Asia Pacific
                        7.2.4. Latin America
                        7.2.5. MEA
                    7.3 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
                        7.3.1. North America
                        7.3.2. Europe
                        7.3.3. Asia Pacific
                        7.3.4. Latin America
                        7.3.5. MEA
                    7.4 North America
                        7.4.1 North America market, 2015 - 2026 (USD Million)
                        7.4.2 U.S.
                            7.4.2.1 U.S. market, 2015 - 2026 (USD Million)
                        7.4.3 Canada
                            7.4.3.1 Canada market, 2015 - 2026 (USD Million)
                    7.5. Europe
                        7.5.1 Europe market, 2015 - 2026 (USD Million)
                        7.5.2 U.K.
                            7.5.2.1 U.K. market, 2015 - 2026 (USD Million)
                        7.5.3 Germany
                            7.5.3.1 Germany market, 2015 - 2026 (USD Million)
                        7.5.4 France
                            7.5.4.1 France market, 2015 - 2026 (USD Million)
                        7.5.5 Italy
                            7.5.5.1 Italy market, 2015 - 2026 (USD Million)
                        7.5.6 Spain
                            7.5.6.1 Spain market, 2015 - 2026 (USD Million)
                    7.6 Asia Pacific
                        7.6.1 Asia Pacific market, 2015 - 2026 (USD Million)
                        7.6.2 Japan
                            7.6.2.1 Japan market, 2015 - 2026 (USD Million)
                        7.6.3 China
                            7.6.3.1 China market, 2015 - 2026 (USD Million)
                        7.6.4 South Korea
                            7.6.4.1 South Korea market, 2015 - 2026 (USD Million)
                        7.6.5 Australia
                            7.6.5.1 Australia market, 2015 - 2026 (USD Million)
                    7.7 Latin America
                        7.7.1 Latin America market, 2015 - 2026 (USD Million)
                        7.7.2 Brazil
                            7.7.2.1 Brazil market, 2015 - 2026 (USD Million)
                        7.7.3 Mexico
                            7.7.3.1 Mexico market, 2015 - 2026 (USD Million)
                        7.7.4 Argentina
                            7.7.4.1 Argentina market, 2015 - 2026 (USD Million)
                    7.8 MEA
                        7.8.1 MEA market, 2015 - 2026 (USD Million)
                        7.8.2 South Africa
                            7.8.2.1 South Africa market, 2015 - 2026 (USD Million)
                        7.8.3 UAE
                            7.8.3.1 UAE market, 2015 - 2026 (USD Million)

Chapter 8 Competitive Landscape
                    8.1 Strategy Framework
                    8.2 Heat Map Analysis of Private Companies
                        8.2.1 Company size
                        8.2.2 Distribution network
                        8.2.3 Product portfolio
                        8.2.4 Segment coverage
                        8.2.5 Geographic presence
                        8.2.6 Collaborations
                        8.2.7 Conclusion
                    8.3 Bristol-Myers Squibb Company
                        8.3.1 Company overview
                        8.3.2 Financial performance
                        8.3.3 Product benchmarking
                        8.3.4 Strategic initiatives
                    8.4 Seattle Genetics, Inc.
                        8.4.1 Company overview
                        8.4.2 Financial performance
                        8.4.3 Product benchmarking
                        8.4.4 Strategic initiatives
                    8.5 Merck & Co., Inc.
                        8.5.1 Company overview
                        8.5.2 Financial performance
                        8.5.3 Product benchmarking
                        8.5.4 Strategic initiatives
                    8.6 Celgene Corporation
                        8.6.1 Company overview
                        8.6.2 Financial performance
                        8.6.3 Product benchmarking
                        8.6.4 Strategic initiatives
                    8.7 Takeda Pharmaceutical Company Ltd.
                        8.7.1 Company overview
                        8.7.2 Financial performance
                        8.7.3 Product benchmarking
                        8.7.4 Strategic initiatives
                    8.8 Johnson & Johnson
                        8.8.1 Company overview
                        8.8.2 Financial performance
                        8.8.3 Product benchmarking
                        8.8.4 Strategic initiatives
                    8.9 F. Hoffmann-La Roche Ltd
                        8.9.1 Company overview
                        8.9.2 Financial performance
                        8.9.3 Product benchmarking
                        8.9.4 Strategic initiatives
                    8.10 Abbott Laboratories
                        8.10.1 Company overview
                        8.10.2 Financial performance
                        8.10.3 Product benchmarking
                        8.10.4 Strategic initiatives
                    8.11 Eli Lilly and Company
                        8.11.1 Company overview
                        8.11.2 Financial performance
                        8.11.3 Product benchmarking
                        8.11.4 Strategic initiatives

List of Tables

TABLE 1 Country share estimation
TABLE 2 North America lymphoma treatment market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 3 North America lymphoma treatment market estimates and forecasts, by drug, 2015 - 2026 (USD Million)
TABLE 4 U.S. lymphoma treatment market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 5 U.S. lymphoma treatment market estimates and forecasts, by drug, 2015 - 2026 (USD Million)
TABLE 6 Canada lymphoma treatment market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 7 Canada lymphoma treatment market estimates and forecasts, by drug, 2015 - 2026 (USD Million)
TABLE 8 Europe lymphoma treatment market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 9 Europe lymphoma treatment market estimates and forecasts, by drug, 2015 - 2026 (USD Million)
TABLE 10 U.K. lymphoma treatment Market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 11 U.K. lymphoma treatment market estimates and forecasts, by drug, 2015 - 2026 (USD Million)
TABLE 12 Germany lymphoma treatment Market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 13 Germany lymphoma treatment market estimates and forecasts, by drug, 2015 - 2026 (USD Million)
TABLE 14 France lymphoma treatment Market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 15 France lymphoma treatment market estimates and forecasts, by drug, 2015 - 2026 (USD Million)
TABLE 16 Spain lymphoma treatment Market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 17 Spain lymphoma treatment market estimates and forecasts, by drug, 2015 - 2026 (USD Million)
TABLE 18 Italy lymphoma treatment Market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 19 Italy lymphoma treatment market estimates and forecasts, by drug, 2015 - 2026 (USD Million)
TABLE 20 Asia Pacific lymphoma treatment Market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 21 Asia Pacific lymphoma treatment market estimates and forecasts, by drug, 2015 - 2026 (USD Million)
TABLE 22 Japan lymphoma treatment Market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 23 Japan lymphoma treatment market estimates and forecasts, by drug, 2015 - 2026 (USD Million)
TABLE 24 China lymphoma treatment Market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 25 China lymphoma treatment market estimates and forecasts, by drug, 2015 - 2026 (USD Million)
TABLE 26 South Korea lymphoma treatment Market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 27 South Korea lymphoma treatment market estimates and forecasts, by drug, 2015 - 2026 (USD Million)
TABLE 28 Australia lymphoma treatment Market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 29 Australia lymphoma treatment market estimates and forecasts, by drug, 2015 - 2026 (USD Million)
TABLE 30 Latin America lymphoma treatment Market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 31 Latin America lymphoma treatment market estimates and forecasts, by drug, 2015 - 2026 (USD Million)
TABLE 32 Brazil lymphoma treatment Market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 33 Brazil lymphoma treatment market estimates and forecasts, by drug, 2015 - 2026 (USD Million)
TABLE 34 Mexico lymphoma treatment Market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 35 Mexico lymphoma treatment market estimates and forecasts, by drug, 2015 - 2026 (USD Million)
TABLE 36 Argentina lymphoma treatment Market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 37 Argentina lymphoma treatment market estimates and forecasts, by drug, 2015 - 2026 (USD Million)
TABLE 38 Middle East & Africa lymphoma treatment Market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 39 Middle East & Africa lymphoma treatment market estimates and forecasts, by drug, 2015 - 2026 (USD Million)
TABLE 40 South Africa treatment Market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 41 South Africa lymphoma treatment market estimates and forecasts, by drug, 2015 - 2026 (USD Million)
TABLE 42 UAE lymphoma treatment Market estimates and forecasts, by type, 2015 - 2026 (USD Million)
TABLE 43 UAE lymphoma treatment market estimates and forecasts, by drug, 2015 - 2026 (USD Million)

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Market summary, 2018
FIG. 4 Market trends & outlook
FIG. 5 Market segmentation & scope
FIG. 6 Market driver relevance analysis (Current & future impact)
FIG. 7 Market restrain relevance analysis (Current & future impact)
FIG. 8 Penetration & growth prospect mapping
FIG. 9 SWOT analysis, by factor (Political & legal, economic, and technological)
FIG. 10 Porter's five forces analysis
FIG. 11 Lymphoma treatment market type outlook key takeaways
FIG. 12 Lymphoma treatment market: Type movement analysis
FIG. 13 Global Hodgkin lymphoma market, 2015 - 2026 (USD Million)
FIG. 14 Global non-Hodgkin lymphoma market, 2015 - 2026 (USD Million)
FIG. 15 Lymphoma treatment market drug outlook key takeaways
FIG. 16 Lymphoma Treatment market: Drug movement analysis
FIG. 17 Global Adcetris market, 2015 - 2026 (USD Million)
FIG. 18 Global Opdivo market, 2015 - 2026 (USD Million)
FIG. 19 Global Rituxan/MabThera market, 2015 - 2026 (USD Million)
FIG. 20 Global Imbruvica market, 2015 - 2026 (USD Million)
FIG. 21 Global Keytruda market, 2015 - 2026 (USD Million)
FIG. 22 Global Revlimid market, 2015 - 2026 (USD Million)
FIG. 23 Global others market, 2015 - 2026 (USD Million)
FIG. 24 Regional market place: Key takeaways, 2018
FIG. 25 Regional outlook, 2018 & 2026
FIG. 26 North America lymphoma treatment Market, 2015 - 2026 (USD Million)
FIG. 27 U.S. lymphoma treatment market, 2015 - 2026 (USD Million)
FIG. 28 Canada lymphoma treatment market, 2015 - 2026 (USD Million)
FIG. 29 Europe lymphoma treatment market, 2015 - 2026 (USD Million)
FIG. 30 U.K. lymphoma treatment market, 2015 - 2026 (USD Million)
FIG. 31 Germany lymphoma treatment market, 2015 - 2026 (USD Million)
FIG. 32 France lymphoma treatment market, 2015 - 2026 (USD Million)
FIG. 33 Spain lymphoma treatment market, 2015 - 2026 (USD Million)
FIG. 34 Italy lymphoma treatment market, 2015 - 2026 (USD Million)
FIG. 35 Asia Pacific lymphoma treatment market, 2015 - 2026 (USD Million)
FIG. 36 Japan lymphoma treatment market, 2015 - 2026 (USD Million)
FIG. 37 China lymphoma treatment market, 2015 - 2026 (USD Million)
FIG. 38 South Korea lymphoma treatment market, 2015 - 2026 (USD Million)
FIG. 39 Australia lymphoma treatment market, 2015 - 2026 (USD Million)
FIG. 40 Latin America lymphoma treatment market, 2015 - 2026 (USD Million)
FIG. 41 Brazil lymphoma treatment market, 2015 - 2026 (USD Million)
FIG. 42 Mexico lymphoma treatment market, 2015 - 2026 (USD Million)
FIG. 43 Argentina lymphoma treatment market, 2015 - 2026 (USD Million)
FIG. 44 Middle East & Africa lymphoma treatment market, 2015 - 2026 (USD Million)
FIG. 45 South Africa lymphoma treatment market, 2015 - 2026 (USD Million)
FIG. 46 UAE lymphoma treatment market, 2015 - 2026 (USD Million)
FIG. 47 Strategy framework
FIG. 48 Participant categorization